Trial reportJournal of clinical immunology2004
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.
Trial report in Journal of clinical immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Antigen-specific active immunotherapy for ovarian cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.Cancer research · 2016Trial
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Trial
- Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation.Experimental hematology & oncology · 2026Review
- Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine Adjuvants.Vaccines · 2026Article
- Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy.Cell death & disease · 2025Review
- Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products.Frontiers in immunology · 2025Article
- Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.Frontiers in immunology · 2025Review
- Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Assessing the immunogenicity risk of salmon calcitonin peptide impurities usingFrontiers in pharmacology · 2024Article
- Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.Pharmaceuticals (Basel, Switzerland) · 2023Review
- B-Cell-Based Immunotherapy: A Promising New Alternative.Vaccines · 2022Review
- Emerging immunotherapeutic strategies for the treatment of breast cancer.Breast cancer research and treatment · 2022Review
- Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Review
- Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines.Experimental and therapeutic medicine · 2021Article
- Development of Therapeutic Vaccines for Ovarian Cancer.Vaccines · 2020Review
- Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.Advanced therapeutics · 2020Article
- MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer.Inflammation · 2019Article
- CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
HER-2/neu is a tumor antigen in patients with breast and ovarian cancer. Multiple varieties of vaccine strategies are being developed to immunize patients against HER-2/neu. Studies in animal models have demonstrated both T cell and antibody immunity are needed to mediate an antitumor response. Thirty-five patients, immunized with HER-2/neu peptide based vaccines, were evaluated for the generation of HER-2/neu-specific antibody immunity. Sixty percent of patients developed HER-2/neu IgG specific antibody responses to at least one peptide included in their vaccine. Twenty-nine percent of patients developed IgG immunity to the native HER-2/neu protein after peptide immunization. Humoral intramolecular epitope-spreading within the HER-2/neu protein occurred in 49% of immunized patients. Intermolecular epitope-spreading to p53 was evident in 20% of vaccinated patients. Of those patients who developed new immunity to p53, 71% had demonstrated antibody epitope-spreading within HER-2/neu.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.